Referencias Seleccionadas

Artículos de Revisión

Brod, S., Lindsey, J. W.,Wolinsky, J. S. 1996. Multiple Sclerosis: Clinical Presentation, Diagnosis and Treatment. American Family Physician ,54:1301-1311.

Dinter, H., Onuffer, J., Faulds, D. and Perez H. D. 1997. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. Journal of Molecular Medicine, 75:95-102.

Johnson, K. P. 1997. The historical development of interferons as multiple sclerosis therapies. Journal of Molecular Medicine , 75:89-94.

Sawcer, S., Goodfellow, P. N., and Compston, A. 1997. The genetic analysis of multiple sclerosis. Trends in Genetics , 13:234-239.

Stinissen, P., Raus, J., and Zhang, J. 1997. Autoimmune Pathogenesis of Multiple Sclerosis: Role of Autoreactive T Lymphocytes and New Immunotherapeutic Strategies. Critical Reviews in Immunology , 17:33-75.

Documentos de Investigación

Arnon, R., Sela, M. and Teitelbaum, D. 1996. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. Journal of Neurology , 243(Supplement1):S8-S13.

Jacobs, L. D., et al. 1996. Intramusculat Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis. Annals of Neurology ,39:285-294.

Johnson, K. P. 1996. A review of the clinical efficacy profile of copolymer 1: New U. S. phase III trial data. Journal of Neurology , 243 (Supplement1):S3-S7.

Rudick, R. A., et al. 1997. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology , 49:358-363.

Sadovnick, A. D., Ebers, G. C., Dyment, D. A., Risch, N. J., et al. 1996. Evidence for genetic basis of multiple sclerosis. The Lancet ,347:1728-1730.